- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Concluding Thoughts on the Treatment of Dry Eye Disease
Key opinion leaders share their final thoughts on advancing treatments of Dry Eye Disease.
EP: 1.Overview of Dry Eye Disease (DED) Causes and Treatments
EP: 2.Adverse Events & Existing Treatment Options for Dry Eye Disease
EP: 3.Navigating Different Subtypes of Dry Eye Disease
EP: 4.Assessing Efficacy of Treatment Through Patient-Reported Outcomes
EP: 5.Updating Formularies: Considerations for Dry Eye Disease
EP: 6.Assessing the Economic Burden of Under Diagnosed Dry Eye Disease
EP: 7.Identifying Key Socioeconomic Burdens Associated with Dry Eye Disease
EP: 8.Resource Allocation in the Treatment of Dry Eye Disease
EP: 9.Quality of Life & Patient Reported Outcomes in Dry Eye Disease
EP: 10.Annual Health Care Costs of Managing Dry Eye Disease
EP: 11.Novel Treatments Targeting Symptoms & Causes of Dry Eye Disease
EP: 12.Evaluating Treatment Outcomes in Dry Eye Disease
EP: 13.Evaluating Economic Impact of Emerging Therapies for Dry Eye Disease
EP: 14.Concluding Thoughts on the Treatment of Dry Eye Disease
This is a video synopsis/summary of a Stakeholder Summit involving:
Ryan Haumschild, PharmD, MS, MBA; Jai G. Parekh, MD, MBA; and Alexander Kabiri, OD.
Haumschild asks about primary obstacles reducing dry eye disease (DED) treatment effectiveness. Parekh states providers are diagnosing DED, preferred practice guidelines are evolving, and industry innovation continues. However, insurance barriers such as step therapy protocols remain frustrating despite expanding options. This leads to communication breakdowns with patients wrongly ascribing access issues to their provider. He urges payers to demand evidence of efficacy but facilitate access so comprehensive DED care is achievable for every patient subtype. As DED progresses untreated, exponentially costlier specialized treatments become necessary. Early intervention optimizes value.
In concluding key takeaways for stakeholders, Kabiri advocates embracing innovation benefiting large patient subgroups that lowers long-term disease costs. Parekh foresees targeted DED therapies matched to specific deficiencies at the right timepoints with better coverage as the ideal future landscape through continued collaboration across stakeholders to fulfill unmet needs.
Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.
Collaborative Care Model Offers Success in Reducing Suicide Risk, New Report Finds
April 10th 2025A report published today by the American Foundation for Suicide Prevention underscores the potential of the collaborative care model to lower suicide risk across diverse patient populations and health systems.
Read More
Sociodemographic Factors Impact Cytoreductive Surgery Decisions in Advanced Ovarian Cancer
April 9th 2025Patients with advanced epithelial ovarian cancer who were non-Hispanic Black, older, had lower household income, resided in nonmetropolitan areas, and were unmarried had higher odds of refusing cytoreductive surgery.
Read More
Meta-Analysis Finds SGLT2 Inhibitors Boost Hemoglobin, Hematocrit in CKD
April 8th 2025The analysis supports the integration of sodium-glucose cotransporter 2 (SGLT2) inhibitors into treatment paradigms for patients with chronic kidney disease (CKD) not only for their established benefits but also for addressing anemia.
Read More
Worse CTD-PAH Prognosis Seen With Higher HFA-PEFF Score
April 8th 2025The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective tissue disease–associated pulmonary arterial hypertension (CTD-PAH) stratified by their Heart Failure Association–preserved ejection fraction (HFA-PEFF) algorithm score.
Read More
